These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
601 related articles for article (PubMed ID: 8841742)
1. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection. Patel SS; Wagstaff AJ Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742 [TBL] [Abstract][Full Text] [Related]
2. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Matheson AJ; Goa KL Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466 [TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A; Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665 [TBL] [Abstract][Full Text] [Related]
4. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976 [TBL] [Abstract][Full Text] [Related]
5. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants. Simondon F; Yam A; Gagnepain JY; Wassilak S; Danve B; Cadoz M Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):927-32. PubMed ID: 9031875 [TBL] [Abstract][Full Text] [Related]
6. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648 [TBL] [Abstract][Full Text] [Related]
7. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640 [TBL] [Abstract][Full Text] [Related]
8. Randomised controlled trial of combined diphtheria, tetanus, whole-cell pertussis vaccine administered in the same syringe and separately with Haemophilus influenzae type b vaccine at two, three and four months of age. Jones IG; Tyrrell H; Hill A; Horobin JM; Taylor B Vaccine; 1998 Jan; 16(1):109-13. PubMed ID: 9607017 [TBL] [Abstract][Full Text] [Related]
9. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483 [TBL] [Abstract][Full Text] [Related]
10. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748 [TBL] [Abstract][Full Text] [Related]
13. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938 [TBL] [Abstract][Full Text] [Related]
14. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa). Dhillon S BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea. Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828 [TBL] [Abstract][Full Text] [Related]
16. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants. Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224 [TBL] [Abstract][Full Text] [Related]
17. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy. Korkmaz HA; Aydin A; Unal B Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L; Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171 [TBL] [Abstract][Full Text] [Related]
19. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780 [TBL] [Abstract][Full Text] [Related]
20. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]